Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
19. September 2022 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next...
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07. September 2022 09:15 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
01. September 2022 16:15 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
16. August 2022 21:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Second Quarter 2022 Financial Results
12. August 2022 07:00 ET
|
Iterum Therapeutics plc
--Enrollment in Registration Trial for uUTI to Begin Q4 2022-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq:...
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA
11. Juli 2022 07:30 ET
|
Iterum Therapeutics plc
--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial Expected to Begin Enrollment in Q4 2022-- DUBLIN,...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06. Juli 2022 16:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, July 06, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14. Juni 2022 17:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports First Quarter 2022 Financial Results
13. Mai 2022 07:00 ET
|
Iterum Therapeutics plc
-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May 13, 2022 (GLOBE NEWSWIRE) -- Iterum...
Iterum Therapeutics Provides Regulatory Update
11. Mai 2022 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...